RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
2.240
-0.070 (-3.03%)
At close: Apr 23, 2025, 4:00 PM
2.200
-0.040 (-1.79%)
Pre-market: Apr 24, 2025, 4:38 AM EDT
RedHill Biopharma Employees
RedHill Biopharma had 35 employees as of December 31, 2024. The number of employees decreased by 18 or -33.96% compared to the previous year.
Employees
35
Change (1Y)
-18
Growth (1Y)
-33.96%
Revenue / Employee
$229,800
Profits / Employee
-$236,229
Market Cap
3.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
RDHL News
- 6 days ago - RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PRNewsWire
- 8 days ago - RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption - PRNewsWire
- 13 days ago - RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights - PRNewsWire
- 5 weeks ago - RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation - PRNewsWire
- 6 weeks ago - RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results - PRNewsWire
- 7 weeks ago - RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum - PRNewsWire
- 2 months ago - RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties - PRNewsWire
- 2 months ago - RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer - PRNewsWire